Som en konsekvens af øget insulinfølsomhed kan patienter, der modtager pioglitazone i kombination med insulin, have risiko for at få dosisrelateret hypoglykæmi, og en reduktion i dosis kan være nødvendig.
As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of insulin may be necessary.